CJC-1295 (No DAC) 5mg
Research Overview
CJC-1295 (No DAC) is a synthetic growth hormone-releasing hormone (GHRH) analogue studied in research models involving growth hormone axis regulation, pituitary signaling, pulsatile hormone secretion, endocrine physiology, and peptide receptor biology.
Designed without a Drug Affinity Complex (DAC), CJC-1295 (No DAC) is investigated for its shorter pharmacokinetic profile and its ability to support research into physiologic growth hormone pulsatility. Its receptor selectivity has made it an important research peptide for examining endocrine signaling and growth hormone secretagogue pathways.
Lyophilized Vial Format
Precision-manufactured and lyophilized for stability, this research-grade peptide is produced to support reproducible laboratory workflows requiring accurate preparation, controlled storage, and consistent experimental performance.
Why Researchers Study CJC-1295 (No DAC)
CJC-1295 (No DAC) is investigated for its interaction with growth hormone-releasing hormone receptors located within the anterior pituitary. By selectively activating the GHRH pathway without the prolonged half-life associated with DAC-conjugated variants, researchers are able to examine endocrine signaling under conditions that more closely reflect normal physiologic hormone release patterns.
Its pharmacological profile has established CJC-1295 (No DAC) as a valuable research tool for studying pituitary physiology, growth hormone regulation, peptide receptor biology, and the molecular mechanisms that coordinate endocrine communication.
Research Applications
Researchers commonly utilize CJC-1295 (No DAC) in laboratory investigations involving:
- Growth hormone-releasing hormone (GHRH) signaling
- Pituitary physiology
- Growth hormone axis regulation
- Pulsatile hormone secretion
- Endocrine signaling
- Peptide receptor biology
- Neuroendocrine research
- Hormonal feedback mechanisms
- Metabolic endocrinology
- Experimental hormone physiology
